We are experts in plasminogen research

Omnio AB is a biopharmaceutical company specialized in development of new drug products based on the protein plasminogen that regulates inflammation and have immune enhancing effects.

More about us


Omino is led by a team of life science entrepreneurs with extensive experience in immunology, partnerships and drug discovery collaborations.

Read more

Drug Development

Omnio is developing recombinant plasminogen for treatment of chronic wounds.

Read more

Wound healing

The management of chronic wounds is an enormous clinical and economic burden on the health care system.

Read more

Clinical development plan

We focus on delivering transformative treatment for chronic wounds and where there is little to no pharmacologically active treatment available today.

Read more